Search

Your search keyword '"Betteridge, N."' showing total 100 results
Start Over Author "Betteridge, N." Publication Year Range Last 50 years
100 results on '"Betteridge, N."'

3. Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making

Author

Taylor PC, Betteridge N, Brown TM, Woolcott J, Kivitz AJ, Zerbini C, Whalley D, Olayinka-Amao O, Chen C, Dahl P, Ponce de Leon D, Gruben D, and Fallon L

Subjects
drug administration, patient perspective, qualitative research, surveys, Medicine (General), R5-920
Abstract

Peter C Taylor, 1 Neil Betteridge, 2 T Michelle Brown, 3 John Woolcott, 4 Alan J Kivitz, 5 Cristiano Zerbini, 6 Diane Whalley, 7 Oyebimpe Olayinka-Amao, 3 Connie Chen, 8 Palle Dahl, 9 Dario Ponce de Leon, 10 David Gruben, 11 Lara Fallon 12 1Botnar Research Centre, University of Oxford, Oxford, UK; 2Neil Betteridge Associates, London, UK; 3Patient-Centered Outcomes Assessment Group, RTI Health Solutions, Research Triangle Park, NC, USA; 4Patient and Health Impact, Health Economics and Outcomes Research, Pfizer Inc, Collegeville, PA, USA; 5Altoona Center for Clinical Research, Duncansville, PA, USA; 6Department of Rheumatology, Centro Paulista De Investigação Clinica, São Paulo, Brazil; 7Patient-Centered Outcomes Assessment Group, RTI Health Solutions, Manchester, UK; 8Xeljanz, Rheumatology, Inflammation & Immunology Medical Affairs, Pfizer Inc, New York, NY, USA; 9Medical Affairs, International Developed Markets, Inflammation & Immunology, Pfizer Inc, Ballerup, Denmark; 10Medical Affairs Latin-America, Pfizer Inc, New York, NY, USA; 11Statistical Research and Data Science Center, Pfizer Inc, Groton, CT, USA; 12Global Medical Affairs, Pfizer Inc, Montreal, QC, CanadaCorrespondence: Peter C TaylorBotnar Research Centre, University of Oxford, Windmill Road, Headington, Oxford OX3 7LD, UKTel +441865 227323Email peter.taylor@kennedy.ox.ac.ukPurpose: Current knowledge of the reasons for patients’ preference for rheumatoid arthritis (RA) treatment modes is limited. This study was designed to identify preferences for four treatment modes, and to obtain in-depth information on the reasons for these preferences.Patients and Methods: In this multi-national, cross-sectional, qualitative study, in-depth interviews were conducted with adult patients with RA in the United States, France, Germany, Italy, Spain, Switzerland, the United Kingdom, and Brazil. Patients’ strength of preference was evaluated using a 100-point allocation task (0– 100; 100=strongest) across four treatment modes: oral, self-injection, clinic-injection, and infusion. Qualitative descriptive analysis methods were used to identify, characterize, and summarize patterns found in the interview data relating to reasons for these preferences.Results: 100 patients were interviewed (female, 75.0%; mean age, 53.9 years; mean 11.6 years since diagnosis). Among the four treatment modes, oral administration was allocated the highest mean (standard deviation) preference points (47.3 [33.1]) and was ranked first choice by the greatest percentage of patients (57.0%), followed by self-injection (29.7 [27.7]; 29.0%), infusion (15.4 [24.6]; 16.0%), and clinic-injection (7.5 [14.1]; 2.0%). Overall, 56.0% of patients had a “strong” first-choice preference (ie, point allocation ≥ 70); most of these patients chose oral (62.5%) vs self-injection (23.2%), infusion (10.7%), or clinic-injection (3.6%). Speed and/or ease of administration were the most commonly reported reasons for patients choosing oral (52.6%) or self-injection (55.2%). The most common reasons for patients not choosing oral or self-injection were not wanting to take another pill (37.2%) and avoiding pain due to needles (46.5%), respectively.Conclusion: These data report factors important to patients regarding preferences for RA treatment modes. Patients may benefit from discussions with their healthcare professionals and/or patient support groups, regarding RA treatment modes, to facilitate shared decision-making.Keywords: drug administration, patient perspective, qualitative research, surveys

Published
2020

5. POS0466 INTERIM UPDATE ON BASELINE CHARACTERISTICS AND EFFECTIVENESS FROM A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA) TREATED WITH FILGOTINIB (FILOSOPHY)

Author

Caporali, R., primary, Avouac, J., additional, Bevers, K., additional, Burmester, G. R., additional, Debray, T., additional, De Leonardis, F., additional, Harris, K., additional, Betteridge, N., additional, Romero-Yuste, S., additional, Verschueren, P., additional, Zignani, M., additional, and Galloway, J., additional

Published
2023
Full Text
View/download PDF

6. Global, regional, and national burden of rheumatoid arthritis, 1990-2020, and projections to 2050:a systematic analysis of the Global Burden of Disease Study 2021

Author

Black, RJ, Cross, M, Haile, LM, Culbreth, G, Steinmetz, J, Hagins, H, Kopec, JA, Brooks, PM, Woolf, A, Ong, KL, Kopansky-Giles, DR, Dreinhoefer, KE, Betteridge, N, Aali, A, Abbasifard, M, Abbasi-Kangevari, M, Abdurehman, AM, Abedi, A, Abidi, H, Aboagye, RG, Abolhassani, H, Abu-Gharbieh, E, Abu-Zaid, A, Adamu, K, Addo, IY, Afzal, MS, Ahmed, A, Charalampous, P, Gupta, S, Gupta, VK, Hill, CL, Hussain, S, Khan, MJ, Kim, YJ, Kisa, A, Lim, SS, Malik, AA, Nguyen, CT, Rahman, MHU, Singh, A, Singh, JA, Singh, S, Tan, KK, Wu, AM, Yonemoto, N, You, YY, Zhang, ZI, Vos, T, Black, RJ, Cross, M, Haile, LM, Culbreth, G, Steinmetz, J, Hagins, H, Kopec, JA, Brooks, PM, Woolf, A, Ong, KL, Kopansky-Giles, DR, Dreinhoefer, KE, Betteridge, N, Aali, A, Abbasifard, M, Abbasi-Kangevari, M, Abdurehman, AM, Abedi, A, Abidi, H, Aboagye, RG, Abolhassani, H, Abu-Gharbieh, E, Abu-Zaid, A, Adamu, K, Addo, IY, Afzal, MS, Ahmed, A, Charalampous, P, Gupta, S, Gupta, VK, Hill, CL, Hussain, S, Khan, MJ, Kim, YJ, Kisa, A, Lim, SS, Malik, AA, Nguyen, CT, Rahman, MHU, Singh, A, Singh, JA, Singh, S, Tan, KK, Wu, AM, Yonemoto, N, You, YY, Zhang, ZI, and Vos, T

Abstract

Background: Rheumatoid arthritis is a chronic autoimmune inflammatory disease associated with disability and premature death. Up-to-date estimates of the burden of rheumatoid arthritis are required for health-care planning, resource allocation, and prevention. As part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021, we provide updated estimates of the prevalence of rheumatoid arthritis and its associated deaths and disability-adjusted life-years (DALYs) by age, sex, year, and location, with forecasted prevalence to 2050. Methods: Rheumatoid arthritis prevalence was estimated in 204 countries and territories from 1990 to 2020 using Bayesian meta-regression models and data from population-based studies and medical claims data (98 prevalence and 25 incidence studies). Mortality was estimated from vital registration data with the Cause of Death Ensemble model (CODEm). Years of life lost (YLL) were calculated with use of standard GBD lifetables, and years lived with disability (YLDs) were estimated from prevalence, a meta-analysed distribution of rheumatoid arthritis severity, and disability weights. DALYs were calculated by summing YLLs and YLDs. Smoking was the only risk factor analysed. Rheumatoid arthritis prevalence was forecast to 2050 by logistic regression with Socio-Demographic Index as a predictor, then multiplying by projected population estimates. Findings: In 2020, an estimated 17·6 million (95% uncertainty interval 15·8–20·3) people had rheumatoid arthritis worldwide. The age-standardised global prevalence rate was 208·8 cases (186·8–241·1) per 100 000 population, representing a 14·1% (12·7–15·4) increase since 1990. Prevalence was higher in females (age-standardised female-to-male prevalence ratio 2·45 [2·40–2·47]). The age-standardised death rate was 0·47 (0·41–0·54) per 100 000 population (38 300 global deaths [33 500–44 000]), a 23·8% (17·5–29·3) decrease from 1990 to 2020. The 2020 DALY count was 3 060 000 (2 320 000–3

Published
2023

10. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update

Author

Gossec, L, Smolen, J S, Ramiro, S, de Wit, M, Cutolo, M, Dougados, M, Emery, P, Landewé, R, Oliver, S, Aletaha, D, Betteridge, N, Braun, J, Burmester, G, Cañete, J D, Damjanov, N, FitzGerald, O, Haglund, E, Helliwell, P, Kvien, T K, Lories, R, Luger, T, Maccarone, M, Marzo-Ortega, H, McGonagle, D, McInnes, I B, Olivieri, I, Pavelka, K, Schett, G, Sieper, J, van den Bosch, F, Veale, D J, Wollenhaupt, J, Zink, A, and van der Heijde, D

Published
2016
Full Text
View/download PDF

11. Health systems strengthening to arrest the global disability burden: empirical development of prioritised components for a global strategy for improving musculoskeletal health

Author

Briggs, AM, Schneider, CH, Slater, H, Jordan, JE, Parambath, S, Young, JJ, Sharma, S, Kopansky-Giles, D, Mishrra, S, Akesson, KE, Ali, N, Belton, J, Betteridge, N, Blyth, FM, Brown, R, Debere, D, Dreinhofer, KE, Finucane, L, Foster, HE, Gimigliano, F, Haldeman, S, Haq, SA, Horgan, B, Jain, A, Joshipura, M, Kalla, AA, Lothe, J, Matsuda, S, Mobasheri, A, Mwaniki, L, Nordin, MC, Pattison, M, Reis, FJJ, Soriano, ER, Tick, H, Waddell, J, Wiek, D, Woolf, AD, March, L, Briggs, AM, Schneider, CH, Slater, H, Jordan, JE, Parambath, S, Young, JJ, Sharma, S, Kopansky-Giles, D, Mishrra, S, Akesson, KE, Ali, N, Belton, J, Betteridge, N, Blyth, FM, Brown, R, Debere, D, Dreinhofer, KE, Finucane, L, Foster, HE, Gimigliano, F, Haldeman, S, Haq, SA, Horgan, B, Jain, A, Joshipura, M, Kalla, AA, Lothe, J, Matsuda, S, Mobasheri, A, Mwaniki, L, Nordin, MC, Pattison, M, Reis, FJJ, Soriano, ER, Tick, H, Waddell, J, Wiek, D, Woolf, AD, and March, L

Abstract

INTRODUCTION: Despite the profound burden of disease, a strategic global response to optimise musculoskeletal (MSK) health and guide national-level health systems strengthening priorities remains absent. Auspiced by the Global Alliance for Musculoskeletal Health (G-MUSC), we aimed to empirically derive requisite priorities and components of a strategic response to guide global and national-level action on MSK health. METHODS: Design: mixed-methods, three-phase design.Phase 1: qualitative study with international key informants (KIs), including patient representatives and people with lived experience. KIs characterised the contemporary landscape for MSK health and priorities for a global strategic response.Phase 2: scoping review of national health policies to identify contemporary MSK policy trends and foci.Phase 3: informed by phases 1-2, was a global eDelphi where multisectoral panellists rated and iterated a framework of priorities and detailed components/actions. RESULTS: Phase 1: 31 KIs representing 25 organisations were sampled from 20 countries (40% low and middle income (LMIC)). Inductively derived themes were used to construct a logic model to underpin latter phases, consisting of five guiding principles, eight strategic priority areas and seven accelerators for action.Phase 2: of the 165 documents identified, 41 (24.8%) from 22 countries (88% high-income countries) and 2 regions met the inclusion criteria. Eight overarching policy themes, supported by 47 subthemes, were derived, aligning closely with the logic model.Phase 3: 674 panellists from 72 countries (46% LMICs) participated in round 1 and 439 (65%) in round 2 of the eDelphi. Fifty-nine components were retained with 10 (17%) identified as essential for health systems. 97.6% and 94.8% agreed or strongly agreed the framework was valuable and credible, respectively, for health systems strengthening. CONCLUSION: An empirically derived framework, co-designed and strongly supported by multisectoral stakeh

Published
2021

12. Health systems strengthening to arrest the global disability burden:empirical development of prioritised components for a global strategy for improving musculoskeletal health

Author

Briggs, A. M. (Andrew M.), Huckel Schneider, C. (Carmen), Slater, H. (Helen), Jordan, J. E. (Joanne E), Parambath, S. (Sarika), Young, J. J. (James J.), Sharma, S. (Saurab), Kopansky- Giles, D. (Deborah), Mishrra, S. (Swatee), Akesson, K. E. (Kristina E.), Ali, N. (Nuzhat), Belton, J. (Joletta), Betteridge, N. (Neil), Blyth, F. M. (Fiona M.), Brown, R. (Richard), Debere, D. (Demelash), Dreinhöfer, K. E. (Karsten E.), Finucane, L. (Laura), Foster, H. E. (Helen E.), Gimigliano, F. (Francesca), Haldeman, S. (Scott), Haq, S. A. (Syed A.), Horgan, B. (Ben), Jain, A. (Anil), Joshipura, M. (Manjul), Kalla, A. A. (Asgar A.), Lothe, J. (Jakob), Matsuda, S. (Shuichi), Mobasheri, A. (Ali), Mwaniki, L. (Lillian), Nordin, M. C. (Margareta C.), Pattison, M. (Marilyn), Reis, F. J. (Felipe J. J.), Soriano, E. R. (Enrique R.), Tick, H. (Heather), Waddell, J. (James), Wiek, D. (Dieter), Woolf, A. D. (Anthony D.), March, L. (Lyn), Briggs, A. M. (Andrew M.), Huckel Schneider, C. (Carmen), Slater, H. (Helen), Jordan, J. E. (Joanne E), Parambath, S. (Sarika), Young, J. J. (James J.), Sharma, S. (Saurab), Kopansky- Giles, D. (Deborah), Mishrra, S. (Swatee), Akesson, K. E. (Kristina E.), Ali, N. (Nuzhat), Belton, J. (Joletta), Betteridge, N. (Neil), Blyth, F. M. (Fiona M.), Brown, R. (Richard), Debere, D. (Demelash), Dreinhöfer, K. E. (Karsten E.), Finucane, L. (Laura), Foster, H. E. (Helen E.), Gimigliano, F. (Francesca), Haldeman, S. (Scott), Haq, S. A. (Syed A.), Horgan, B. (Ben), Jain, A. (Anil), Joshipura, M. (Manjul), Kalla, A. A. (Asgar A.), Lothe, J. (Jakob), Matsuda, S. (Shuichi), Mobasheri, A. (Ali), Mwaniki, L. (Lillian), Nordin, M. C. (Margareta C.), Pattison, M. (Marilyn), Reis, F. J. (Felipe J. J.), Soriano, E. R. (Enrique R.), Tick, H. (Heather), Waddell, J. (James), Wiek, D. (Dieter), Woolf, A. D. (Anthony D.), and March, L. (Lyn)

Abstract

Introduction: Despite the profound burden of disease, a strategic global response to optimise musculoskeletal (MSK) health and guide national-level health systems strengthening priorities remains absent. Auspiced by the Global Alliance for Musculoskeletal Health (G-MUSC), we aimed to empirically derive requisite priorities and components of a strategic response to guide global and national-level action on MSK health. Methods: Design: mixed-methods, three-phase design. Phase 1: qualitative study with international key informants (KIs), including patient representatives and people with lived experience. KIs characterised the contemporary landscape for MSK health and priorities for a global strategic response. Phase 2: scoping review of national health policies to identify contemporary MSK policy trends and foci. Phase 3: informed by phases 1–2, was a global eDelphi where multisectoral panellists rated and iterated a framework of priorities and detailed components/actions. Results: Phase 1: 31 KIs representing 25 organisations were sampled from 20 countries (40% low and middle income (LMIC)). Inductively derived themes were used to construct a logic model to underpin latter phases, consisting of five guiding principles, eight strategic priority areas and seven accelerators for action. Phase 2: of the 165 documents identified, 41 (24.8%) from 22 countries (88% high-income countries) and 2 regions met the inclusion criteria. Eight overarching policy themes, supported by 47 subthemes, were derived, aligning closely with the logic model. Phase 3: 674 panellists from 72 countries (46% LMICs) participated in round 1 and 439 (65%) in round 2 of the eDelphi. Fifty-nine components were retained with 10 (17%) identified as essential for health systems. 97.6% and 94.8% agreed or strongly agreed the framework was valuable and credible, respectively, for health systems strengthening. Conclusion: An empirically derived framework, co-designed and strongly supported by multis

Published
2021

15. Improving quality of care in rheumatoid arthritis and associated comorbidities

Author

Kvien, T.K., Balsa, A., Betteridge, N., Buch, M., Dougados, M., Durez, P., Favalli, E., Favier, G., Gabay, C., Geenen, R., Gouni-Berthold, I., van den Hoogen, F., Kent, A., Klareskog, L., Ostergaard, M., Pavelka, K., Polido-Pereira, J., Semb, A.G., Skold, M., Clinical Psychology (onderzoeksprogramma), and Leerstoel Geenen

Abstract

This report presents examples of good practice interventions that aim to improve the quality of life for patients with RA and associated comorbidities in Europe. The KPMG team interviewed rheumatologists and other healthcare professionals in a number of centres involved in RA patient care. In collaboration with a multidisciplinary steering committee, comprised of rheumatologists, comorbidity specialists, a rheumatology nurse and a patient representative, features of good practice were identified across the patient pathway and documented in the report. It outlines practices that promote early diagnosis and support the effective management of RA and associated comorbidities to improve outcomes for patients.

Published
2020

16. Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities

Author

Kvien, T.K., Balsa, A., Betteridge, N., Buch, M., Durez, P., Favalli, E., Favier, G., Gabay, C., Geenen, R., Gouni-Berthold, I., van den Hoogen, F., Kent, A., Klareskog, L., Ostergaard, M., Pavelka, K., Polido-Pereira, J., Semb, A., Skold, M., Dougados, M., Kvien, T.K., Balsa, A., Betteridge, N., Buch, M., Durez, P., Favalli, E., Favier, G., Gabay, C., Geenen, R., Gouni-Berthold, I., van den Hoogen, F., Kent, A., Klareskog, L., Ostergaard, M., Pavelka, K., Polido-Pereira, J., Semb, A., Skold, M., and Dougados, M.

Abstract

Objective: Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disorder with a global prevalence of approximately 0.5-1%. Patients with RA are at an increased risk of developing comorbidities (eg, cardiovascular disease, pulmonary disease, diabetes and depression). Despite this, there are limited recommendations for the management and implementation of associated comorbidities. This study aimed to identify good practice interventions in the care of RA and associated comorbidities. Methods: A combination of primary research (180+ interviews with specialists across 12 European rheumatology centres) and secondary research (literature review of existing publications and guidelines/recommendations) were used to identify challenges in management and corresponding good practice interventions. Findings were prioritised and reviewed by a group of 18 rheumatology experts including rheumatologists, comorbidity experts, a patient representative and a highly specialised nurse. Results: Challenges throughout the patient pathway (including delays in diagnosis and referral, shortage of rheumatologists, limited awareness of primary care professionals) and 18 good practice interventions were identified in the study. The expert group segmented and prioritised interventions according to three distinct stages of the disease: (1) suspected RA, (2) recent diagnosis of RA and (3) established RA. Examples of good practice interventions included enabling self-management (self-monitoring and disease management support, for example, lifestyle adaptations); early arthritis clinic; rapid access to care (online referral, triage, ultrasound-guided diagnosis); dedicated comorbidity specialists; enhanced communication with primary care (hotline, education sessions); and integrating patient registries into daily clinical practice. Conclusion: Learning from implementation of good practice interventions in centres across Europe provides an opportunity to more widel

Published
2020

17. Improving quality of care in rheumatoid arthritis and associated comorbidities

Author

Clinical Psychology (onderzoeksprogramma), Leerstoel Geenen, Kvien, T.K., Balsa, A., Betteridge, N., Buch, M., Dougados, M., Durez, P., Favalli, E., Favier, G., Gabay, C., Geenen, R., Gouni-Berthold, I., van den Hoogen, F., Kent, A., Klareskog, L., Ostergaard, M., Pavelka, K., Polido-Pereira, J., Semb, A.G., Skold, M., Clinical Psychology (onderzoeksprogramma), Leerstoel Geenen, Kvien, T.K., Balsa, A., Betteridge, N., Buch, M., Dougados, M., Durez, P., Favalli, E., Favier, G., Gabay, C., Geenen, R., Gouni-Berthold, I., van den Hoogen, F., Kent, A., Klareskog, L., Ostergaard, M., Pavelka, K., Polido-Pereira, J., Semb, A.G., and Skold, M.

Published
2020

18. Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities

Author

Clinical Psychology (onderzoeksprogramma), Leerstoel Geenen, Kvien, T.K., Balsa, A., Betteridge, N., Buch, M., Durez, P., Favalli, E., Favier, G., Gabay, C., Geenen, R., Gouni-Berthold, I., van den Hoogen, F., Kent, A., Klareskog, L., Ostergaard, M., Pavelka, K., Polido-Pereira, J., Semb, A., Skold, M., Dougados, M., Clinical Psychology (onderzoeksprogramma), Leerstoel Geenen, Kvien, T.K., Balsa, A., Betteridge, N., Buch, M., Durez, P., Favalli, E., Favier, G., Gabay, C., Geenen, R., Gouni-Berthold, I., van den Hoogen, F., Kent, A., Klareskog, L., Ostergaard, M., Pavelka, K., Polido-Pereira, J., Semb, A., Skold, M., and Dougados, M.

Published
2020

20. THU0579 “EVOLVING THE MANAGEMENT OF RA” PROGRAMME: EDUCATIONAL TOOLS TO SUPPORT DAILY PRACTICE

Author

Burmester, G. R., primary, Alvaro-Gracia, J. M., additional, Betteridge, N., additional, Calvo, J., additional, Combe, B., additional, Durez, P., additional, Ferreira, R. J. O., additional, Fautrel, B., additional, Iagnocco, A., additional, Montecucco, C., additional, Ǿstergaard, M., additional, Ramiro, S., additional, Rubbert-Roth, A., additional, Stamm, T., additional, Szekanecz, Z., additional, Taylor, P. C., additional, and Van de Laar, M., additional

Published
2020
Full Text
View/download PDF

28. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force

Author

Smolen, J.S. (Josef S.), Schöls, M. (Monika), Braun, J. (Jürgen), Dougados, M. (Maxime), FitzGerald, E.V.K., Gladman, D.D. (Dafna D.), Kavanaugh, A. (Arthur), Landewé, R. (Robert), Mease, P. (Philip), Sieper, J. (Joachim), Stamm, T. (Tanja), Wit, M. (Maarten de), Aletaha, D. (Daniel), Baraliakos, X. (Xenofon), Betteridge, N. (Neil), Bosch, F.V.D. (Filip van den), Coates, L.C. (Laura C.), Emery, P. (Paul), Gensler, L.S. (Lianne S.), Gossec, L. (Laure), Helliwell, P. (Philip), Jongkees, M. (Merryn), Kvien, T.K. (Tore K.), Inman, R.D. (Robert D.), McInnes, I.B. (Iain), MacCarone, M., Machado, P.M. (Pedro M.), Molto, A. (Anna), Ogdie, A. (Alexis), Poddubnyy, D. (Denis), Ritchlin, C. (Christopher), Rudwaleit, M. (Martin), Tanew, A. (Adrian), Thio, B.H. (Bing), Veale, D. (Douglas), Vlam, K. (Kurt de), Heijde, D.V. (Désirée van der), Smolen, J.S. (Josef S.), Schöls, M. (Monika), Braun, J. (Jürgen), Dougados, M. (Maxime), FitzGerald, E.V.K., Gladman, D.D. (Dafna D.), Kavanaugh, A. (Arthur), Landewé, R. (Robert), Mease, P. (Philip), Sieper, J. (Joachim), Stamm, T. (Tanja), Wit, M. (Maarten de), Aletaha, D. (Daniel), Baraliakos, X. (Xenofon), Betteridge, N. (Neil), Bosch, F.V.D. (Filip van den), Coates, L.C. (Laura C.), Emery, P. (Paul), Gensler, L.S. (Lianne S.), Gossec, L. (Laure), Helliwell, P. (Philip), Jongkees, M. (Merryn), Kvien, T.K. (Tore K.), Inman, R.D. (Robert D.), McInnes, I.B. (Iain), MacCarone, M., Machado, P.M. (Pedro M.), Molto, A. (Anna), Ogdie, A. (Alexis), Poddubnyy, D. (Denis), Ritchlin, C. (Christopher), Rudwaleit, M. (Martin), Tanew, A. (Adrian), Thio, B.H. (Bing), Veale, D. (Douglas), Vlam, K. (Kurt de), and Heijde, D.V. (Désirée van der)

Abstract

Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but the evidence for these recommendations was only of indirect nature. These recommendations were re-evaluated in light of new insights. Based on the results of a systematic literature review and expert opinion, a task force of rheumatologists, dermatologists, patients and a health professional developed an update of the 2012 recommendations. These underwent intensive discussions, on site voting and subsequent anonymous electronic voting on levels of agreement with each item. A set of 5 overarching principles and 11 recommendations were developed and voted on. Some items were present in the previous recommendations, while others were significantly changed or newly formulated. The 2017 task force arrived at a single set of recommendations for axial and peripheral SpA, including psoriatic arthritis (PsA). The most exhaustive discussions related to whether PsA should be assessed using unidimensional composite scores for its different domains or multidimensional scores that comprise multiple domains. This question was not resolved and constitutes an important research agenda. There was broad agreement, now better supported by data than in 2012, that remission/inactive disease and, alternatively, low/minimal disease activity are the principal targets for the treatment of PsA. As instruments to assess the patients on the path to the target, the Ankylosing Spondylitis Disease Activity Score (ASDAS) for axial SpA and the Disease Activity index for PSoriatic Arthritis (DAPSA) and Minimal Disease Activity (MDA) for PsA were recommended, although not supported by all. Shared decision-making between the clinician and the patient was seen as pivotal to the process. The task force defined the treatment target for SpA as remission or low disease activity and developed a large research agenda to further advance the field.

Published
2018
Full Text
View/download PDF

29. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force

Author

Smolen, JS, Schoels, M, Braun, J, Dougados, M, FitzGerald, O, Gladman, DD, Kavanaugh, A, Landewe, R, Mease, P, Sieper, J, Stamm, T, de Wit, Maurice, Aletaha, D, Baraliakos, X, Betteridge, N, Bosch, F, Coates, LC, Emery, P, Gensler, LS, Gossec, L, Helliwell, P, Jongkees, M, Kvien, TK, Inman, RD, McInnes, IB, Maccarone, M, Machado, PM, Molto, A, Ogdie, A, Poddubnyy, D, Ritchlin, C, Rudwaleit, M, Tanew, A, Thio, Bing, Veale, D, de Vlam, K, van der Heijde, D, Smolen, JS, Schoels, M, Braun, J, Dougados, M, FitzGerald, O, Gladman, DD, Kavanaugh, A, Landewe, R, Mease, P, Sieper, J, Stamm, T, de Wit, Maurice, Aletaha, D, Baraliakos, X, Betteridge, N, Bosch, F, Coates, LC, Emery, P, Gensler, LS, Gossec, L, Helliwell, P, Jongkees, M, Kvien, TK, Inman, RD, McInnes, IB, Maccarone, M, Machado, PM, Molto, A, Ogdie, A, Poddubnyy, D, Ritchlin, C, Rudwaleit, M, Tanew, A, Thio, Bing, Veale, D, de Vlam, K, and van der Heijde, D

Published
2018

32. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force

Author

Smolen, J.S. Breedveld, F.C. Burmester, G.R. Bykerk, V. Dougados, M. Emery, P. Kvien, T.K. Navarro-Compán, M.V. Oliver, S. Schoels, M. Scholte-Voshaar, M. Stamm, T. Stoffer, M. Takeuchi, T. Aletaha, D. Andreu, J.L. Aringer, M. Bergman, M. Betteridge, N. Bijlsma, H. Burkhardt, H. Cardiel, M. Combe, B. Durez, P. Fonseca, J.E. Gibofsky, A. Gomez-Reino, J.J. Graninger, W. Hannonen, P. Haraoui, B. Kouloumas, M. Landewe, R. Martin-Mola, E. Nash, P. Ostergaard, M. Östör, A. Richards, P. Sokka-Isler, T. Thorne, C. Tzioufas, A.G. Van Vollenhoven, R. De Wit, M. Van Der Heijde, D.

Abstract

Background: Reaching the therapeutic target of remission or low-disease activity has improved outcomes in patients with rheumatoid arthritis (RA) significantly. The treat-to-target recommendations, formulated in 2010, have provided a basis for implementation of a strategic approach towards this therapeutic goal in routine clinical practice, but these recommendations need to be re-evaluated for appropriateness and practicability in the light of new insights. Objective: To update the 2010 treat-to-target recommendations based on systematic literature reviews (SLR) and expert opinion. Methods: A task force of rheumatologists, patients and a nurse specialist assessed the SLR results and evaluated the individual items of the 2010 recommendations accordingly, reformulating many of the items. These were subsequently discussed, amended and voted upon by >40 experts, including 5 patients, from various regions of the world. Levels of evidence, strengths of recommendations and levels of agreement were derived. Results: The update resulted in 4 overarching principles and 10 recommendations. The previous recommendations were partly adapted and their order changed as deemed appropriate in terms of importance in the view of the experts. The SLR had now provided also data for the effectiveness of targeting low-disease activity or remission in established rather than only early disease. The role of comorbidities, including their potential to preclude treatment intensification, was highlighted more strongly than before. The treatment aim was again defined as remission with low-disease activity being an alternative goal especially in patients with long-standing disease. Regular follow-up (every 1-3 months during active disease) with according therapeutic adaptations to reach the desired state was recommended. Follow-up examinations ought to employ composite measures of disease activity that include joint counts. Additional items provide further details for particular aspects of the disease, especially comorbidity and shared decision-making with the patient. Levels of evidence had increased for many items compared with the 2010 recommendations, and levels of agreement were very high for most of the individual recommendations (≥9/10). Conclusions: The 4 overarching principles and 10 recommendations are based on stronger evidence than before and are supposed to inform patients, rheumatologists and other stakeholders about strategies to reach optimal outcomes of RA.

Published
2016

33. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis

Author

Buch, M. h., Smolen, J. s., Betteridge, N., Breedveld, F. c., Burmester, G., Dorner, T., Ferraccioli, G., Gottenberg, J. e., Isaacs, J., Kvien, T. k., Mariette, X., Martin Mola, E., Pavelka, K., Tak, P. p., Van Der Heijde, D., Van Vollenhoven, R. f., Emery, P., Carbonell Abello, Rituximab Consensus Expert Committee (., Bukhari, M., Burkhardt, H., Combe, B., Gomez Reino Carnota, J. j., Barile Fabris, L., Klareskog, L., Marenco De La Fuente, J. l., Montecucco, C. m., Mikkel, Ostergaard, Pascual Gomez, E., Sanmarti Sala, R., Tony, Hp, Valesini, Guido, Van Laar, J., Van Riel, P., and Faculteit der Geneeskunde

Subjects
rheumatoid arthritis, juvenile idiopathic arthritis chronic hepatitis-b progressive multifocal leukoencephalopathy antitumor necrosis factor late-onset neutropenia modifying antirheumatic drugs systemic-lupus-erythematosus rapid-infusion rituximab synovial tissue-response non-hodgkins-lymphoma, medicine.medical_specialty, Settore MED/16 - REUMATOLOGIA, Consensus, Immunology, MEDLINE, Disease, General Biochemistry, Genetics and Molecular Biology, Drug Administration Schedule, Arthritis, Rheumatoid, Antibodies, Monoclonal, Murine-Derived, Rheumatology, medicine, Immunology and Allergy, Humans, Intensive care medicine, Glucocorticoids, Randomized Controlled Trials as Topic, B cells, Evidence-Based Medicine, business.industry, Evidence-based medicine, medicine.disease, Clinical trial, Antirheumatic Agents, Systematic review, Treatment Outcome, Rheumatoid arthritis, Physical therapy, Rituximab, Drug Therapy, Combination, business, medicine.drug
Abstract

BackgroundSince initial approval for the treatment of rheumatoid arthritis (RA), rituximab has been evaluated in clinical trials involving various populations with RA. Information has also been gathered from registries. This report therefore updates the 2007 consensus document on the use of rituximab in the treatment of RA.MethodsPreparation of this new document involved many international experts experienced in the treatment of RA. Following a meeting to agree upon the core agenda, a systematic literature review was undertaken to identify all relevant data. Data were then interrogated by a drafting committee, with subsequent review and discussion by a wider expert committee leading to the formulation of an updated consensus statement. These committees also included patients with RA.ResultsThe new statement covers wide-ranging issues including the use of rituximab in earlier RA and impact on structural progression, and aspects particularly pertinent to rituximab such as co-medication, optimal dosage regimens, repeat treatment cycles and how to manage non-response. Biological therapy following rituximab usage is also addressed, and safety concerns including appropriate screening for hepatitis, immunoglobulin levels and infection risk. This consensus statement will support clinicians and inform patients when using B-cell depletion in the management of RA, providing up-to-date information and highlighting areas for further research.ConclusionNew therapeutic strategies and treatment options for RA, a chronic destructive and disabling disease, have expanded over recent years. These have been summarised in general strategic suggestions and specific management recommendations, emphasising the importance of expedient disease-modifying antirheumatic drug implementation and tight disease control. This consensus statement is in line with these fundamental principles of management.

Published
2011
Full Text
View/download PDF

34. Treating rheumatoid arthritis to target

Author

Smolen, Josef S., Breedveld, F.C., Burmester, G.R., Bykerk, V., Dougados, M., Emery, P., Kvien, T.K., Navarro-Compán, M.V., Oliver, S., Schoels, M., Scholte-Voshaar, M., Stamm, T., Stoffer, M., Takeuchi, T., Aletaha, D., Andreu, J.L., Aringer, M., Bergman, M., Betteridge, N., Bijlsma, H., Burkhardt, H., Cardiel, M., Combe, B., Durez, P., Fonseca, J.E., Gibofsky, A., Gomez-Reino, J.J., Graninger, W., Hannonen, P., Haraoui, B., Kouloumas, M., Landewe, R., Martin-Mola, E., Nash, P., Ostergaard, M., Östör, A., Richards, P., Sokka-Isler, T., Thorne, C., Tzioufas, A.G., Vollenhoven, R. van, Wit, M. de, Heijde, van der, and Publica

Abstract

Background:Background Reaching the therapeutic target of remission or low-disease activity has improved outcomes in patients with rheumatoid arthritis (RA) significantly. The treat-to-target recommendations, formulated in 2010, have provided a basis for implementation of a strategic approach towards this therapeutic goal in routine clinical practice, but these recommendations need to be re-evaluated for appropriateness and practicability in the light of new insights. Objective: To update the 2010 treat-to-target recommendations based on systematic literature reviews (SLR) and expert opinion. Methods: A task force of rheumatologists, patients and a nurse specialist assessed the SLR results and evaluated the individual items of the 2010 recommendations accordingly, reformulating many of the items. These were subsequently discussed, amended and voted upon by >40 experts, including 5 patients, from various regions of the world. Levels of evidence, strengths of recommendations and levels of agreement were derived. Results: The update resulted in 4 overarching principles and 10 recommendations. The previous recommendations were partly adapted and their order changed as deemed appropriate in terms of importance in the view of the experts. The SLR had now provided also data for the effectiveness of targeting low-disease activity or remission in established rather than only early disease. The role of comorbidities, including their potential to preclude treatment intensification, was highlighted more strongly than before. The treatment aim was again defined as remission with low-disease activity being an alternative goal especially in patients with long-standing disease. Regular follow-up (every 1-3 months during active disease) with according therapeutic adaptations to reach the desired state was recommended. Follow-up examinations ought to employ composite measures of disease activity that include joint counts. Additional items provide further details for particular aspects of the disease, especially comorbidity and shared decision-making with the patient. Levels of evidence had increased for many items compared with the 2010 recommendations, and levels of agreement were very high for most of the individual recommendations (>9/10). Conclusions: The 4 overarching principles and 10 recommendations are based on stronger evidence than before and are supposed to inform patients, rheumatologists and other stakeholders about strategies to reach optimal outcomes of RA. Reaching the therapeutic target of remission or low-disease activity has improved outcomes in patients with rheumatoid arthritis (RA) significantly. The treat-to-target recommendations, formulated in 2010, have provided a basis for implementation of a strategic approach towards this therapeutic goal in routine clinical practice, but these recommendations need to be re-evaluated for appropriateness and practicability in the light of new insights. Objective To update the 2010 treat-to-target recommendations based on systematic literature reviews (SLR) and expert opinion. Methods A task force of rheumatologists, patients and a nurse specialist assessed the SLR results and evaluated the individual items of the 2010 recommendations accordingly, reformulating many of the items. These were subsequently discussed, amended and voted upon by >40 experts, including 5 patients, from various regions of the world. Levels of evidence, strengths of recommendations and levels of agreement were derived. Results The update resulted in 4 overarching principles and 10 recommendations. The previous recommendations were partly adapted and their order changed as deemed appropriate in terms of importance in the view of the experts. The SLR had now provided also data for the effectiveness of targeting low-disease activity or remission in established rather than only early disease. The role of comorbidities, including their potential to preclude treatment intensification, was highlighted more strongly than before. The treatment aim was again defined as remission with low-disease activity being an alternative goal especially in patients with long-standing disease. Regular follow-up (every 1-3 months during active disease) with according therapeutic adaptations to reach the desired state was recommended. Follow-up examinations ought to employ composite measures of disease activity that include joint counts. Additional items provide further details for particular aspects of the disease, especially comorbidity and shared decision-making with the patient. Levels of evidence had increased for many items compared with the 2010 recommendations, and levels of agreement were very high for most of the individual recommendations (>9/10). Conclusions The 4 overarching principles and 10 recommendations are based on stronger evidence than before and are supposed to inform patients, rheumatologists and other stakeholders about strategies to reach optimal outcomes of RA.

Published
2015

35. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies : 2015 update

Author

Gossec, L., Smolen, J. S., Ramiro, S., de Wit, M., Cutolo, M., Dougados, M., Emery, P., Landewé, R., Oliver, S., Aletaha, D., Betteridge, N., Braun, J., Burmester, G., Cañete, J. D., Damjanov, N., FitzGerald, O., Haglund, Emma, Helliwell, P., Kvien, T. K., Lories, R., Luger, T., Maccarone, M., Marzo-Ortega, H., McGonagle, D., McInnes, I. B., Olivieri, I., Pavelka, K., Schett, G., Sieper, J., van den Bosch, F., Veale, D. J., Wollenhaupt, J., Zink, A., van der Heijde, D., Gossec, L., Smolen, J. S., Ramiro, S., de Wit, M., Cutolo, M., Dougados, M., Emery, P., Landewé, R., Oliver, S., Aletaha, D., Betteridge, N., Braun, J., Burmester, G., Cañete, J. D., Damjanov, N., FitzGerald, O., Haglund, Emma, Helliwell, P., Kvien, T. K., Lories, R., Luger, T., Maccarone, M., Marzo-Ortega, H., McGonagle, D., McInnes, I. B., Olivieri, I., Pavelka, K., Schett, G., Sieper, J., van den Bosch, F., Veale, D. J., Wollenhaupt, J., Zink, A., and van der Heijde, D.

Abstract

BACKGROUND: Since the publication of the European League Against Rheumatism recommendations for the pharmacological treatment of psoriatic arthritis (PsA) in 2012, new evidence and new therapeutic agents have emerged. The objective was to update these recommendations. METHODS: A systematic literature review was performed regarding pharmacological treatment in PsA. Subsequently, recommendations were formulated based on the evidence and the expert opinion of the 34 Task Force members. Levels of evidence and strengths of recommendations were allocated. RESULTS: The updated recommendations comprise 5 overarching principles and 10 recommendations, covering pharmacological therapies for PsA from non-steroidal anti-inflammatory drugs (NSAIDs), to conventional synthetic (csDMARD) and biological (bDMARD) disease-modifying antirheumatic drugs, whatever their mode of action, taking articular and extra-articular manifestations of PsA into account, but focusing on musculoskeletal involvement. The overarching principles address the need for shared decision-making and treatment objectives. The recommendations address csDMARDs as an initial therapy after failure of NSAIDs and local therapy for active disease, followed, if necessary, by a bDMARD or a targeted synthetic DMARD (tsDMARD). The first bDMARD would usually be a tumour necrosis factor (TNF) inhibitor. bDMARDs targeting interleukin (IL)12/23 (ustekinumab) or IL-17 pathways (secukinumab) may be used in patients for whom TNF inhibitors are inappropriate and a tsDMARD such as a phosphodiesterase 4-inhibitor (apremilast) if bDMARDs are inappropriate. If the first bDMARD strategy fails, any other bDMARD or tsDMARD may be used. CONCLUSIONS: These recommendations provide stakeholders with an updated consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes in PsA, based on a combination of evidence and expert opinion. © 2015 BMJ Publishing Group Ltd & European League Against Rheumatism., Funding by EULAR (grant CLI079).

Published
2016
Full Text
View/download PDF

36. Consensus statement on the use of rituximab in patients with rheumatoid arthritis

Author

Smolen, J. S., Keystone, E. C., Emery, P., Breedveld, F. C., Betteridge, N., Burmester, G. R., Dougados, M., Ferraccioli, G., Jaeger, U., Klareskog, L., Kvien, T. K., Martin Mola, E., Pavelka, K., Carbonell, Jordi, Combe, Bernard, Cutolo, Maurizio, Dörner, Thomas, Gause, Angela, Gomez Reino, Juan, Fernandes, Carlos Gonzales, Isaacs, John D., Marenco, José Luis, Mariette, Xavier, Matucci Cerinic, Marco, Montecucco, Carlo Maurizio, Nüßlein, Hubert, Østergaard, Mikkel, Pascual, Eliseo, Van Riel, Piet, Rubbert, Andrea, Sanmarti, Raimon, Sekanecz, Zoltan, Tak, Paul Peter, Tony, Hans Peter, Valesini, Guido, VALENTINI, Gabriele, Smolen, J. S., Keystone, E. C., Emery, P., Breedveld, F. C., Betteridge, N., Burmester, G. R., Dougados, M., Ferraccioli, G., Jaeger, U., Klareskog, L., Kvien, T. K., Martin Mola, E., Pavelka, K., Carbonell, Jordi, Combe, Bernard, Cutolo, Maurizio, Dörner, Thoma, Gause, Angela, Gomez Reino, Juan, Fernandes, Carlos Gonzale, Isaacs, John D., Marenco, José Lui, Mariette, Xavier, Matucci Cerinic, Marco, Montecucco, Carlo Maurizio, Nüßlein, Hubert, Østergaard, Mikkel, Pascual, Eliseo, Van Riel, Piet, Rubbert, Andrea, Sanmarti, Raimon, Sekanecz, Zoltan, Tak, Paul Peter, Tony, Hans Peter, Valentini, Gabriele, and Valesini, Guido

Subjects
musculoskeletal diseases, medicine.medical_specialty, Statement (logic), Immunology, MEDLINE, Arthritis, Review, General Biochemistry, Genetics and Molecular Biology, Drug Administration Schedule, Arthritis, Rheumatoid, Antibodies, Monoclonal, Murine-Derived, Rheumatology, Internal medicine, medicine, Immunology and Allergy, Humans, Intensive care medicine, business.industry, Patient Selection, Antirheumatic Agent, Antibodies, Monoclonal, medicine.disease, Clinical trial, Antirheumatic Agents, Rheumatoid arthritis, Physical therapy, Rituximab, business, medicine.drug, Human
Abstract

A large number of experts experienced in the treatment of rheumatoid arthritis were involved in formulating a consensus statement on the use of B cell-targeted treatment with rituximab in patients with rheumatoid arthritis. The statement was supported by data from randomised controlled clinical trials and the substantial literature on oncology. The statement underwent three rounds of discussions until its ultimate formulation. It should guide clinicians in the use of this newly approved biological agent in treating patients with rheumatoid arthritis.

Published
2006

37. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update

Author

Gossec, L, primary, Smolen, J S, additional, Ramiro, S, additional, de Wit, M, additional, Cutolo, M, additional, Dougados, M, additional, Emery, P, additional, Landewé, R, additional, Oliver, S, additional, Aletaha, D, additional, Betteridge, N, additional, Braun, J, additional, Burmester, G, additional, Cañete, J D, additional, Damjanov, N, additional, FitzGerald, O, additional, Haglund, E, additional, Helliwell, P, additional, Kvien, T K, additional, Lories, R, additional, Luger, T, additional, Maccarone, M, additional, Marzo-Ortega, H, additional, McGonagle, D, additional, McInnes, I B, additional, Olivieri, I, additional, Pavelka, K, additional, Schett, G, additional, Sieper, J, additional, van den Bosch, F, additional, Veale, D J, additional, Wollenhaupt, J, additional, Zink, A, additional, and van der Heijde, D, additional

Published
2015
Full Text
View/download PDF

40. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Author

Smolen, J.S., Landewe, R., Breedveld, F.C., Buch, M., Burmester, G., Dougados, M., Emery, P., Gaujoux-Viala, C., Gossec, L., Nam, J., Ramiro, S., Winthrop, K., Wit, M. de, Aletaha, D., Betteridge, N., Bijlsma, J.W.J., Boers, M., Buttgereit, F., Combe, B., Cutolo, M., Damjanov, N., Hazes, J.M., Kouloumas, M., Kvien, T.K., Mariette, X., Pavelka, K., Riel, P.L.C.M. van, Rubbert-Roth, A., Scholte-Voshaar, M., Scott, D.L., Sokka-Isler, T., Wong, J.B., Heijde, D. van der, Smolen, J.S., Landewe, R., Breedveld, F.C., Buch, M., Burmester, G., Dougados, M., Emery, P., Gaujoux-Viala, C., Gossec, L., Nam, J., Ramiro, S., Winthrop, K., Wit, M. de, Aletaha, D., Betteridge, N., Bijlsma, J.W.J., Boers, M., Buttgereit, F., Combe, B., Cutolo, M., Damjanov, N., Hazes, J.M., Kouloumas, M., Kvien, T.K., Mariette, X., Pavelka, K., Riel, P.L.C.M. van, Rubbert-Roth, A., Scholte-Voshaar, M., Scott, D.L., Sokka-Isler, T., Wong, J.B., and Heijde, D. van der

Abstract

Contains fulltext : 137860.pdf (publisher's version ) (Open Access), In this article, the 2010 European League against Rheumatism (EULAR) recommendations for the management of rheumatoid arthritis (RA) with synthetic and biological disease-modifying antirheumatic drugs (sDMARDs and bDMARDs, respectively) have been updated. The 2013 update has been developed by an international task force, which based its decisions mostly on evidence from three systematic literature reviews (one each on sDMARDs, including glucocorticoids, bDMARDs and safety aspects of DMARD therapy); treatment strategies were also covered by the searches. The evidence presented was discussed and summarised by the experts in the course of a consensus finding and voting process. Levels of evidence and grades of recommendations were derived and levels of agreement (strengths of recommendations) were determined. Fourteen recommendations were developed (instead of 15 in 2010). Some of the 2010 recommendations were deleted, and others were amended or split. The recommendations cover general aspects, such as attainment of remission or low disease activity using a treat-to-target approach, and the need for shared decision-making between rheumatologists and patients. The more specific items relate to starting DMARD therapy using a conventional sDMARD (csDMARD) strategy in combination with glucocorticoids, followed by the addition of a bDMARD or another csDMARD strategy (after stratification by presence or absence of adverse risk factors) if the treatment target is not reached within 6 months (or improvement not seen at 3 months). Tumour necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, biosimilars), abatacept, tocilizumab and, under certain circumstances, rituximab are essentially considered to have similar efficacy and safety. If the first bDMARD strategy fails, any other bDMARD may be used. The recommendations also address tofacitinib as a targeted sDMARD (tsDMARD), which is recommended, where licensed, after use of at least one b

Published
2014

41. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Author

Smolen, J.S. (Josef), Landewé, R.B.M. (Robert), Breedveld, F.C. (Ferdinand), Buch, T. (Thorsten), Burmester, G.R. (Gerd), Dougados, M. (Maxime), Emery, P. (Paul), Gaujoux-Viala, C. (Cécile), Gossec, L. (Laure), Nam, N. (Nguyen) van, Ramiro, S. (Sofia), Winthrop, K. (Kevin), M. de Wit (Maarten), Aletaha, D. (Daniel), Betteridge, N. (Neil), Bijlsma, J.W.J. (Hans), Boers, M. (Maarten), Buttgereit, F. (Frank), Combe, B. (Bernard), Cutolo, M. (Maurizio), Damjanov, N. (Nemanja), Hazes, J.M.W. (Mieke), Kouloumas, M. (Marios), Kvien, T.K. (Tore), Mariette, X. (Xavier), Pavelka, K. (Karel), Riel, P.L.C.M. (Piet) van, Rubbert-Roth, A. (Andrea), Scholte-Voshaar, M. (Marieke), Scott, D.L. (David), Sokka-Isler, T. (Tuulikki), Wong, J.B. (John), Heijde, D. (Desiree) van der, Smolen, J.S. (Josef), Landewé, R.B.M. (Robert), Breedveld, F.C. (Ferdinand), Buch, T. (Thorsten), Burmester, G.R. (Gerd), Dougados, M. (Maxime), Emery, P. (Paul), Gaujoux-Viala, C. (Cécile), Gossec, L. (Laure), Nam, N. (Nguyen) van, Ramiro, S. (Sofia), Winthrop, K. (Kevin), M. de Wit (Maarten), Aletaha, D. (Daniel), Betteridge, N. (Neil), Bijlsma, J.W.J. (Hans), Boers, M. (Maarten), Buttgereit, F. (Frank), Combe, B. (Bernard), Cutolo, M. (Maurizio), Damjanov, N. (Nemanja), Hazes, J.M.W. (Mieke), Kouloumas, M. (Marios), Kvien, T.K. (Tore), Mariette, X. (Xavier), Pavelka, K. (Karel), Riel, P.L.C.M. (Piet) van, Rubbert-Roth, A. (Andrea), Scholte-Voshaar, M. (Marieke), Scott, D.L. (David), Sokka-Isler, T. (Tuulikki), Wong, J.B. (John), and Heijde, D. (Desiree) van der

Published
2014
Full Text
View/download PDF

42. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Author

Smolen, JS, Landewe, R, Breedveld, FC, Buch, M, Burmester, G, Dougados, M, Emery, P, Gaujoux-Viala, C, Gossec, L, Nam, J, Ramiro, S, Winthrop, K, de Wit, M, Aletaha, D, Betteridge, N, Bijlsma, JWJ, Boers, M, Buttgereit, F, Combe, B, Cutolo, M, Damjanov, N, Hazes, Mieke, Kouloumas, M, Kvien, TK, Mariette, X, Pavelka, K, van Riel, PLCM, Rubbert-Roth, A, Scholte-Voshaar, M, Scott, DL, Sokka-Isler, T, Wong, JB, van der Heijde, D, Smolen, JS, Landewe, R, Breedveld, FC, Buch, M, Burmester, G, Dougados, M, Emery, P, Gaujoux-Viala, C, Gossec, L, Nam, J, Ramiro, S, Winthrop, K, de Wit, M, Aletaha, D, Betteridge, N, Bijlsma, JWJ, Boers, M, Buttgereit, F, Combe, B, Cutolo, M, Damjanov, N, Hazes, Mieke, Kouloumas, M, Kvien, TK, Mariette, X, Pavelka, K, van Riel, PLCM, Rubbert-Roth, A, Scholte-Voshaar, M, Scott, DL, Sokka-Isler, T, Wong, JB, and van der Heijde, D

Abstract

In this article, the 2010 European League against Rheumatism (EULAR) recommendations for the management of rheumatoid arthritis (RA) with synthetic and biological disease-modifying antirheumatic drugs (sDMARDs and bDMARDs, respectively) have been updated. The 2013 update has been developed by an international task force, which based its decisions mostly on evidence from three systematic literature reviews (one each on sDMARDs, including glucocorticoids, bDMARDs and safety aspects of DMARD therapy); treatment strategies were also covered by the searches. The evidence presented was discussed and summarised by the experts in the course of a consensus finding and voting process. Levels of evidence and grades of recommendations were derived and levels of agreement (strengths of recommendations) were determined. Fourteen recommendations were developed (instead of 15 in 2010). Some of the 2010 recommendations were deleted, and others were amended or split. The recommendations cover general aspects, such as attainment of remission or low disease activity using a treat-to-target approach, and the need for shared decision-making between rheumatologists and patients. The more specific items relate to starting DMARD therapy using a conventional sDMARD (csDMARD) strategy in combination with glucocorticoids, followed by the addition of a bDMARD or another csDMARD strategy (after stratification by presence or absence of adverse risk factors) if the treatment target is not reached within 6months (or improvement not seen at 3months). Tumour necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, biosimilars), abatacept, tocilizumab and, under certain circumstances, rituximab are essentially considered to have similar efficacy and safety. If the first bDMARD strategy fails, any other bDMARD may be used. The recommendations also address tofacitinib as a targeted sDMARD (tsDMARD), which is recommended, where licensed, after use of at least one bDM

Published
2014

43. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

Author

Smolen, J, Schoels, Mm, Nishimoto, N, Breedveld, Fc, Burmester, Gr, Dougados, M, Emery, P, Ferraccioli, Gianfranco, Gabay, C, Gibofsky, A, Gomez Reino, Jj, Jones, G, Kvien, Tk, Murakami, M, Betteridge, N, Bingham, Co, Bykerk, V, Choy, Eh, Combe, B, Cutolo, M, Graninger, W, Lanas, A, Martin Mola, E, Montecucco, C, Ostergaard, M, Pavelka, K, Rubbert Roth, A, Sattar, N, Scholte Voshaar, M, Tanaka, Y, Trauner, M, Valentini, G, Winthrop, Kl, De Wit, M, Van Der Heijde, D., Ferraccioli, Gianfranco (ORCID:0000-0001-6246-2428), Smolen, J, Schoels, Mm, Nishimoto, N, Breedveld, Fc, Burmester, Gr, Dougados, M, Emery, P, Ferraccioli, Gianfranco, Gabay, C, Gibofsky, A, Gomez Reino, Jj, Jones, G, Kvien, Tk, Murakami, M, Betteridge, N, Bingham, Co, Bykerk, V, Choy, Eh, Combe, B, Cutolo, M, Graninger, W, Lanas, A, Martin Mola, E, Montecucco, C, Ostergaard, M, Pavelka, K, Rubbert Roth, A, Sattar, N, Scholte Voshaar, M, Tanaka, Y, Trauner, M, Valentini, G, Winthrop, Kl, De Wit, M, Van Der Heijde, D., and Ferraccioli, Gianfranco (ORCID:0000-0001-6246-2428)

Abstract

Since approval of tocilizumab (TCZ) for treatment of rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), interleukin 6 (IL-6) pathway inhibition was evaluated in trials of TCZ and other agents targeting the IL-6 receptor and ligand in various RA populations and other inflammatory diseases. This consensus document informs on interference with the IL-6 pathway based on evidence and expert opinion.

Published
2013

44. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.

Author

Buch, M, Smolen, J, Betteridge, N, Breedveld, Fc, Burmester, G, Dorner, T, Ferraccioli, Gianfranco, Gottenberg, Je, Isaacs, J, Kvien, Tk, Mariette, X, Martin Mola, E, Pavelka, K, Tak, Pp, Van Der Heijde, D, Van Vollenhoven, Rf, Emery, P., Smolen, Js, Ferraccioli, Gianfranco (ORCID:0000-0001-6246-2428), Gottenberg , Je, Kvien , Tk, Van Vollenhoven , Rf, Buch, M, Smolen, J, Betteridge, N, Breedveld, Fc, Burmester, G, Dorner, T, Ferraccioli, Gianfranco, Gottenberg, Je, Isaacs, J, Kvien, Tk, Mariette, X, Martin Mola, E, Pavelka, K, Tak, Pp, Van Der Heijde, D, Van Vollenhoven, Rf, Emery, P., Smolen, Js, Ferraccioli, Gianfranco (ORCID:0000-0001-6246-2428), Gottenberg , Je, Kvien , Tk, and Van Vollenhoven , Rf

Published
2011

47. Health systems strengthening to arrest the global disability burden:Empirical development of prioritised components for a global strategy for improving musculoskeletal health

Author

Marilyn Pattison, Fiona M. Blyth, Anil Jain, Asgar Ali Kalla, Lillian Mwaniki, Joletta Belton, Dieter Wiek, Sarika Parambath, Neil Betteridge, Syed Atiqul Haq, Manjul Joshipura, Deborah Kopansky-Giles, Jakob Lothe, Richard Brown, Joanne Jordan, Laura Finucane, Francesca Gimigliano, Heather Tick, Ben Horgan, Andrew M. Briggs, Kristina Åkesson, Felipe J J Reis, Demelash Debere, James J. Young, Shuichi Matsuda, Helen E. Foster, Scott Haldeman, Saurab Sharma, Margareta Nordin, Karsten Dreinhöfer, Helen Slater, Carmen Huckel Schneider, Nuzhat Ali, Lyn March, Anthony D. Woolf, Enrique R. Soriano, Swatee Mishrra, James P. Waddell, Ali Mobasheri, Briggs, A. M., Huckel Schneider, C., Slater, H., Jordan, J. E., Parambath, S., Young, J. J., Sharma, S., Kopansky-Giles, D., Mishrra, S., Akesson, K. E., Ali, N., Belton, J., Betteridge, N., Blyth, F. M., Brown, R., Debere, D., Dreinhofer, K. E., Finucane, L., Foster, H. E., Gimigliano, F., Haldeman, S., Haq, S. A., Horgan, B., Jain, A., Joshipura, M., Kalla, A. A., Lothe, J., Matsuda, S., Mobasheri, A., Mwaniki, L., Nordin, M. C., Pattison, M., Reis, F. J. J., Soriano, E. R., Tick, H., Waddell, J., Wiek, D., Woolf, A. D., and March, L.

Subjects
Medicine (General), Economic growth, Guiding Principles, qualitative study, Infectious and parasitic diseases, RC109-216, cross-sectional survey, 03 medical and health sciences, R5-920, 0302 clinical medicine, Blueprint, Political science, health system, 030212 general & internal medicine, Health policy, Original Research, 030203 arthritis & rheumatology, Health Policy, Public Health, Environmental and Occupational Health, Health services research, Global strategy, health policy, health services research, Construct (philosophy), Inclusion (education), health systems, Qualitative research
Abstract

IntroductionDespite the profound burden of disease, a strategic global response to optimise musculoskeletal (MSK) health and guide national-level health systems strengthening priorities remains absent. Auspiced by the Global Alliance for Musculoskeletal Health (G-MUSC), we aimed to empirically derive requisite priorities and components of a strategic response to guide global and national-level action on MSK health.MethodsDesign: mixed-methods, three-phase design.Phase 1: qualitative study with international key informants (KIs), including patient representatives and people with lived experience. KIs characterised the contemporary landscape for MSK health and priorities for a global strategic response.Phase 2: scoping review of national health policies to identify contemporary MSK policy trends and foci.Phase 3: informed by phases 1–2, was a global eDelphi where multisectoral panellists rated and iterated a framework of priorities and detailed components/actions.ResultsPhase 1: 31 KIs representing 25 organisations were sampled from 20 countries (40% low and middle income (LMIC)). Inductively derived themes were used to construct a logic model to underpin latter phases, consisting of five guiding principles, eight strategic priority areas and seven accelerators for action.Phase 2: of the 165 documents identified, 41 (24.8%) from 22 countries (88% high-income countries) and 2 regions met the inclusion criteria. Eight overarching policy themes, supported by 47 subthemes, were derived, aligning closely with the logic model.Phase 3: 674 panellists from 72 countries (46% LMICs) participated in round 1 and 439 (65%) in round 2 of the eDelphi. Fifty-nine components were retained with 10 (17%) identified as essential for health systems. 97.6% and 94.8% agreed or strongly agreed the framework was valuable and credible, respectively, for health systems strengthening.ConclusionAn empirically derived framework, co-designed and strongly supported by multisectoral stakeholders, can now be used as a blueprint for global and country-level responses to improve MSK health and prioritise system strengthening initiatives.

Published
2021
Full Text
View/download PDF

48. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

Author

Mikkel Østergaard, Andrea Rubbert-Roth, Bernard Combe, Ferdinand C. Breedveld, Miho Murakami, Michael Trauner, Marieke Scholte-Voshaar, Angel Lanas, Maarten de Wit, Maurizio Cutolo, Gerd R Burmester, Paul Emery, Gabriele Valentini, Juan J. Gomez-Reino, Kevin L. Winthrop, Tore K Kvien, Gianfranco Ferraccioli, Karel Pavelka, Yoshiya Tanaka, Neil Betteridge, Norihiro Nishimoto, Naveed Sattar, Carlomaurizio Montecucco, Ernest Choy, Maxime Dougados, Winfried Graninger, Clifton O. Bingham, Graeme Jones, Désirée van der Heijde, Cem Gabay, Monika Schoels, Josef S Smolen, Allan Gibofsky, Emilio Martín-Mola, Vivian P. Bykerk, Smolen, J, Schoels, Mm, Nishimoto, N, Breedveld, Fc, Burmester, Gr, Dougados, M, Emery, P, Ferraccioli, G, Gabay, C, Gibofsky, A, Gomez Reino, Jj, Jones, G, Kvien, Tk, Murakami, M, Betteridge, N, Bingham C., 3rd, Bykerk, V, Choy, Eh, Combe, B, Cutolo, M, Graninger, W, Lanas, A, Martin Mola, E, Montecucco, C, Ostergaard, M, Pavelka, K, Rubbert Roth, A, Sattar, N, Scholte Voshaar, M, Tanaka, Y, Trauner, M, Valentini, Gabriele, Winthrop, Kl, de Wit, M, van der Heijde, D., Ethics, Law & Medical humanities, and CCA - Innovative therapy

Subjects
musculoskeletal diseases, Settore MED/16 - REUMATOLOGIA, Immunology, MEDLINE, Arthritis, Rheumatoid Arthritis, DMARDs (biologic), Bioinformatics, Antibodies, Monoclonal, Humanized, General Biochemistry, Genetics and Molecular Biology, Arthritis, Rheumatoid, chemistry.chemical_compound, Tocilizumab, Rheumatology, medicine, Immunology and Allergy, Humans, Inflammation/drug therapy/immunology, Antibodies, Monoclonal, Humanized/administration & dosage/adverse effects, Interleukin 6, skin and connective tissue diseases, ddc:616, Inflammation, biology, business.industry, Interleukin-6, Consensus Statement, medicine.disease, Connective tissue disease, Receptors, Interleukin-6, R1, Antirheumatic Agents/administration & dosage/adverse effects, Antirheumatic Agents, Arthritis, Rheumatoid/drug therapy/immunology, Treatment, chemistry, Interleukin-6/antagonists & inhibitors, Rheumatoid arthritis, Interleukin-6 receptor, Receptors, Interleukin-6/antagonists & inhibitors, biology.protein, Drug Monitoring, business, Drug Monitoring/methods
Abstract

Background: Since approval of tocilizumab (TCZ) for treatment of rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), interleukin 6 (IL-6) pathway inhibition was evaluated in trials of TCZ and other agents targeting the IL-6 receptor and ligand in various RA populations and other inflammatory diseases. This consensus document informs on interference with the IL-6 pathway based on evidence and expert opinion.\ud \ud Methods: Preparation of this document involved international experts in RA treatment and RA patients. A systematic literature search was performed that focused on TCZ and other IL6-pathway inhibitors in RA and other diseases. Subsequently, incorporating available published evidence and expert opinion, the steering committee and a broader expert committee (both including RA patients) formulated the current consensus statement.\ud \ud Results: The consensus statement covers use of TCZ as combination- or monotherapy in various RA populations and includes clinical, functional and structural aspects. The statement also addresses the second approved indication in Europe JIA and non-approved indications. Also early phase trials involving additional agents that target the IL-6 receptor or IL-6 were evaluated. Safety concerns, including haematological, hepatic and metabolic issues as well as infections, are addressed likewise.\ud \ud Conclusions: The consensus statement identifies points to consider when using TCZ, regarding indications, contraindications, screening, dose, comedication, response evaluation and safety. The document is aimed at supporting clinicians and informing patients, administrators and payers on opportunities and limitations of IL-6 pathway inhibition.

Published
2013
Full Text
View/download PDF

49. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update.

Author

Aletaha D, Kerschbaumer A, Kastrati K, Dejaco C, Dougados M, McInnes IB, Sattar N, Stamm TA, Takeuchi T, Trauner M, van der Heijde D, Voshaar M, Winthrop KL, Ravelli A, Betteridge N, Burmester GR, Bijlsma JW, Bykerk V, Caporali R, Choy EH, Codreanu C, Combe B, Crow MK, de Wit M, Emery P, Fleischmann RM, Gabay C, Hetland ML, Hyrich KL, Iagnocco A, Isaacs JD, Kremer JM, Mariette X, Merkel PA, Mysler EF, Nash P, Nurmohamed MT, Pavelka K, Poor G, Rubbert-Roth A, Schulze-Koops H, Strangfeld A, Tanaka Y, and Smolen JS

Subjects
Adult, Humans, Arthritis, Rheumatoid drug therapy, COVID-19, Interleukin-6, Still's Disease, Adult-Onset drug therapy, Receptors, Interleukin-6 antagonists & inhibitors, Inflammation drug therapy
Abstract

Background: Targeting interleukin (IL)-6 has become a major therapeutic strategy in the treatment of immune-mediated inflammatory disease. Interference with the IL-6 pathway can be directed at the specific receptor using anti-IL-6Rα antibodies or by directly inhibiting the IL-6 cytokine. This paper is an update of a previous consensus document, based on most recent evidence and expert opinion, that aims to inform on the medical use of interfering with the IL-6 pathway., Methods: A systematic literature research was performed that focused on IL-6-pathway inhibitors in inflammatory diseases. Evidence was put in context by a large group of international experts and patients in a subsequent consensus process. All were involved in formulating the consensus statements, and in the preparation of this document., Results: The consensus process covered relevant aspects of dosing and populations for different indications of IL-6 pathway inhibitors that are approved across the world, including rheumatoid arthritis, polyarticular-course and systemic juvenile idiopathic arthritis, giant cell arteritis, Takayasu arteritis, adult-onset Still's disease, Castleman's disease, chimeric antigen receptor-T-cell-induced cytokine release syndrome, neuromyelitis optica spectrum disorder and severe COVID-19. Also addressed were other clinical aspects of the use of IL-6 pathway inhibitors, including pretreatment screening, safety, contraindications and monitoring., Conclusions: The document provides a comprehensive consensus on the use of IL-6 inhibition to treat inflammatory disorders to inform healthcare professionals (including researchers), patients, administrators and payers., Competing Interests: Competing interests: DA: Grants or contracts from any entity: AbbVie, Amgen, Eli Lilly, Novartis, Roche, SoBi and Sanofi; Consulting fees: AbbVie, Amgen, Eli Lilly, Janssen, Merck, Novartis, Pfizer, Roche and Sandoz; Support for attending meetings and/or travel: AbbVie, Gilead, Sandoz, Pfizer, BMSAK: Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: AbbVie, Bristol-Myers Squibb, Celgene, Eli-Lilly, Gilead, Janssen, Merck Sharp and Dohme, Novartis and PfizerKK: Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Boehringer Ingelheim, UCB Pharma and AbbVie; Support for attending meetings and/or travel: AbbVie, Gilead, Sandoz, Pfizer and BMSJI: Grants or contracts from any entity: Pfizer, GSK and Janssen; Consulting fees: AbbVie, Gilead and BMS; Payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events: AbbVie, Gilead and Roche; Support for attending meetings and/or travel: Eli Lilly and Gilead; Participation on a Data Safety Monitoring Board or Advisory Board: Eli Lilly; Leadership or fiduciary role in other board, society, committee or advocacy group: Versus Arthritis Board member (unpaid) NS: Grants or contracts from any entity: AstraZeneca, Boehringer Ingelheim, Novartis and Roche Diagnostics; Consulting fees: Afimmune, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, MSD, Novartis, Novo Nordisk, Pfizer and SanofiMV: Grants or contracts from any entity: PfizerBC: Grants or contracts from any entity: Pfizer, Roche, Chugai and Novartis; Consulting fees: AbbVie, Celltrion, Janssen, Gilead-Galapagos, Eli Lilly, Novartis, Roche-Chugai; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: AbbVie, BMS, Celltrion, Gilead-Galapagos, Janssen, Eli Lilly, Merck, Pfizer and Roche-ChugaiNB: All support for the present manuscript: Vienna Medical Academy; Consulting fees: Amgen, EULAR, Galapagos, Global Alliance for Patient Access, Grunenthal, Eli Lilly, Pfizer and Sanofi; Support for attending meetings and/or travel: EULAR and Global Alliance for Patient Access; Receipt of equipment, materials, drugs, medical writing, gifts or other services: GalapagosJB: Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Eli Lilly and Galapagos; Participation on a Data Safety Monitoring Board or Advisory Board: SyneosGRB: All support for the present manuscript: Sanofi; Consulting fees: AbbVie, Galapagos, Lilly, Pfizer, Roche and Sanofi; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: AbbVie, Galapagos, Lilly, Pfizer, Roche and SanofiVPB: Grants or contracts from any entity: NIH (NIAID/NIAMS), The Cedar Hill Foundation, Amgen and BMS; Consulting fees: Amgen, BMS, Genzyme, Gilead, Janssen, Pfizer and Sanofi-Aventis; Participation on a Data Safety Monitoring Board or Advisory Board: KAI for NIHRC: noneEC: Grants or contracts from any entity: Bio-Cancer, Biogen, Novartis, Pfizer and Sanofi; Consulting fees: AbbVie, Amgen, BMS, Biocon, Eli Lilly, Galapagos, Chugai Pharma, Janssen, Novartis, Pfizer, Regeneron, Roche, Sanofi and RPharm; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: AbbVie, Amgen, BMS, Chugai Pharma, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, Regeneron, Roche, RPharm and Sanofi; Support for attending meetings and/or travel: Gilead, Galapagos, AbbVie and Eli LillyMT: Grants or contracts from any entity: Albireo, Cymabay, Falk, Gilead, Intercept, MSD, Takeda, Alnylam and Ultragenyx; Consulting fees: Albireo, BioMX, Boehringer Ingelheim, Falk, Genfit, Intercept, Janssen, MSD, Gilead, Novartis, Shire, Phenex and Regulus; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Falk Foundation, Gilead, Intercept and MSD; Support for attending meetings and/or travel: AbbVie, Falk, Gilead and Intercept; Patents planned, issued or pending: Co-Inventor patent on medical use of nor-UDCATS: Grants or contracts from any entity: AbbVie and Roche; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: AbbVie, Roche, Sanofi, Takeda and NovartisCC: Grants or contracts from any entity: AbbVie, Boehringer Ingelheim, Ewopharma, Lilly, Novartis and Pfizer; Consulting fees: AbbVie, Amgen, Boehringer Ingelheim, Ewopharma, Lilly, Novartis and Pfizer; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: AbbVie, Amgen, Boehringer Ingelheim, Ewopharma, Lilly, Novartis and Pfizer; Participation on a Data Safety Monitoring Board or Advisory Board: AbbVie, Amgen, Boehringer Ingelheim, Ewopharma and Pfizer; Leadership or fiduciary role in other board, society, committee or advocacy group: Romanian Society of Rheumatology, Romanian Registry of Rheumatic Diseases and Romanian League against RheumatismMKC: Grants or contracts from any entity: Gilead; Consulting fees: AstraZeneca, BMS, GSK and Shannon Pharmaceuticals; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: AstraZeneca and Gilead; Leadership or fiduciary role in other board, society, committee or advocacy group: Arthritis Foundation, New York Chapter; Stock or stock options: Johnson and Johnson, Regeneron and AmgenMD: All support for the present manuscript: Medical academy of Vienna; Grants or contracts from any entity: Roche, Sanofi, Pfizer, AbbVie, Eli Lilly, BMS, Merck, Galapagos and UCB; Consulting fees: Roche, Sanofi, Pfizer, AbbVie, Eli Lilly, BMS, Merck, Galapagos and UCB; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Roche, Sanofi, Pfizer, AbbVie, Eli Lilly, BMS, Merck, Galapagos and UCBGP: none. DvdH: Consulting fees: AbbVie, Bayer, BMS, Cyxone, Eisai, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Lilly, Novartis, Pfizer and UCB Pharma; Other financial or non-financial interests: Director of Imaging Rheumatology bv.PE: Grants or contracts from any entity: Abbvie, BMS, Lilly, Novartis, Pfizer, Roche and Samsung; Consulting fees: Abbvie, Astra-Zeneca, Boehringer Ingelheim, Galapagos, Gilead, Eli Lilly and Novartis; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Abbvie, BMS, GSK, Eli Lilly and NovartisEM: All support for the present manuscript: University of Vienna funding; Grants or contracts from any entity: Roche, Jansen, Pfizer, AbbVie and Novartis; Consulting fees: GSK, Roche, Novartis, AbbVie, Pfizer, Janssen, Eli Lilly and AstraZeneca; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: GSK, Pfizer, AbbVie, Lilly, Amgen, Janssen and AstraZeneca; Participation on a Data Safety Monitoring Board or Advisory Board: GSKRF: Consulting fees: AbbVie, Amgen, BMS, GSK, Gilead, Pfizer, Novartis and Eli Lilly; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: AbbVie and Pfizer; Participation on a Data Safety Monitoring Board or Advisory Board: AbbVie, Pfizer, Eli Lilly and GSKCG: noneKH: Grants or contracts from any entity: Pfizer and BMS; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: AbbViePAM: Grants or contracts from any entity: AbbVie, AstraZeneca, Boeringher-Ingelheim, Bristol-Myers Squibb, ChemoCentryx, Eicos, Forbius, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, InflaRx, Sanofi and Takeda; Royalties or licenses: UpToDate; Consulting fees: AbbVie, AstraZeneca, Boeringher-Ingelheim, Bristol-Myers Squibb, ChemoCentryx, CSL Behring, Dynacure, EMDSerono, Forbius, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Immagene, InflaRx, Jannsen, Kiniksa, Kyverna, Magenta, MiroBio, Mitsubishi, Neutrolis, Novartis, Pfizer, Regeneron, Sparrow, Takeda and TalarisTT: Grants or contracts from any entity: Chugai Pharmaceutical; Consulting fees: Chugai, Janssen and Rpharma; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Chugai, BMS, Janssen and SanofiXM: Consulting fees: BMS, Novartis, Galapagos, Sanofi, GSK, Pfizer, Janssen and UCBKW: Grants or contracts from any entity: BMS and Pfizer; Consulting fees: AbbVie, BMS, Eli Lily, Galapagos, Gilead, Pfizer, Roche, UCB, GSK, Novartis, AstraZeneca, Regeneron and SanofiMdW: Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Pfizer, Celgene, Eli Lilly and UCBKP: Payments for lectures: Roche, AbbVie, Pfizer, Eli Lilly, Amgen, SOBI, UCB and MSD; Advisory Board: Roche, AbbVie, Pfizer, Eli Lilly, Amgen, SOBI, UCB and MSDPN: Grants or contracts from any entity: Roche, Abbvie, Pfizer, Janssen, Gilead/Galapagos, BMS, Novartis and Eli Lilly; Consulting fees: Abbvie, Pfizer, janssen, BMS, Novartis, Lilly, Roche and Gilead/Galapagos; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Abbvie, Pfizer, janssen, BMS, Novartis, Lilly, Roche and Gilead/GalapagosYT: Grants or contracts from any entity: Asahi-Kasei, Abbvie, Chugai, Mitsubishi-Tanabe, Eisai, Takeda, Corrona, Daiichi-Sankyo, Kowa and Behringer-Ingelheim; Consulting fees: Eli Lilly, Daiichi-Sankyo, Taisho, Ayumi, Sanofi, GSK and Abbvie; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Gilead, AbbVie, Boehringer-Ingelheim, Eli Lilly, Mitsubishi-Tanabe, Chugai, Amgen, YL Biologics, Eisai, Astellas, Bristol-Myers and AstraZenecaCD: Grants or contracts from any entity: FWF Austria and Celgene; Consulting fees: AbbVie, MSD, Pfizer, Roche, Sanofi, Janssen, Novartis, Eli Lilly and Galapagos; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: AbbVie, MSD, Pfizer, Roche, Sanofi, Janssen, Novartis, Eli Lilly and Galapagos; Support for attending meetings and/or travel: AbbVie, MSD, Pfizer, Roche, Sanofi, Janssen, Novartis, Eli Lilly and Galapagos; Receipt of equipment, materials, drugs, medical writing, gifts or other services: MSDMLH: Grants or contracts from any entity: Novartis, Roche and Sandoz; Consulting fees: BMS and Samsung Bioepis; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: MSD, AbbVie, Novartis, Merck, Eli Lilly, Medac and Sandoz; Support for attending meetings and/or travel: The DANBIO registry; Participation on a Data Safety Monitoring Board or Advisory Board: CellTrion and Eli Lilly; Leadership or fiduciary role in other board, society, committee or advocacy group: Chair of the DANBIO steering committee, Member of the Danish Rheumatism Association’s Board, Member of the Danish Rheumatism Association’s research council, Member of EULAR Quality of Care Committee, Co-chair of the EuroSpA collaboration; Receipt of equipment, materials, drugs, medical writing, gifts or other services: Study drug for the NORD-STAR study/ Abatacept and Certolizumab pegolHSK: Consulting fees: Roche, Chugai and Sanofi-Aventis; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Roche, Chugai and Sanofi-Aventis; Participation on a Data Safety Monitoring Board or Advisory Board: Roche, Chugai and Sanofi-AventisMN: Grants or contracts from any entity: Pfizer, Amgen, Galapagos and AbbVie; Consulting fees: AbbVie; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Celgene and AbbVie; Participation on a Data Safety Monitoring Board or Advisory Board: AbbVieAS: Grants or contracts from any entity: oint, unconditional grant from AbbVie, Amgen, BMS, Celltrion, Fresenius Kabi, Hexal, Lilly, MSD, Viatris, Pfizer, Roche, Samsung Bioepis, Sanofi-Aventis and UCB; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: AbbVie, Amgen, BMS, Celltrion, Janssen, Lilly, Pfizer, Roche, Sanofi and UCBAL: Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: AbbVie, MSD, Alfasigma, Celltrion, BMS, Celgene, Eli-Lilly, Sanofi Genzyme, Pfizer, Galapagos, Gilead, Novartis and SOBIAR: Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: AbbVie, Angelini, Pfizer, Novartis, Reckitt Benckiser and SOBI; Leadership or fiduciary role in other board, society, committee or advocacy group: President, Pediatric Rheumatology European Society (PReS)ARR: Consulting fees: Sanofi, Roche, AbbVie, Eli Lilly, Gilead, BMS and Novartis; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: AbbVie, Pfizer, Sanofi, UCB, BMS, Gilead, Roche, Novartis and Janssen; Payment for expert testimony: AbbVie, Novartis and Gilead; Support for attending meetings and/or travel: AbbVie and Sanofi; Participation on a Data Safety Monitoring Board or Advisory Board: RPharmIM: Grants or contracts from any entity: AbbVie, BMS, Eli Lilly, Janssen, Pfizer, UCB, Amgen and Novartis; Consulting fees: AbbVie, BMS, Eli Lilly, Janssen, Pfizer, Sanofi, Novartis, Gilead, Amgen, UCB, GSK and Moonlake; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: AbbVie; Leadership or fiduciary role in other board, society, committee or advocacy group: Vice Principal & Head of MVLS College/University of Glasgow, Board Member/ NHS Greater Glasgow & Clyde and Evelo; Stock or stock options: Causeway Therapeutics, Compugen, Cabaletta and EveloBio; JS: grants to his institution from Abbvie, Astro, AstraZeneca, Janssen, Lilly, Merck Sharpe & Dohme, Pfizer, and Roche; Expert advice for, or had symposia speaking engagements with, AbbVie, Amgen, AstraZeneca, Astro, Bristol-Myers Squibb, Celgene, Celltrion, Chugai, Gilead, ILTOO Pharma, Janssen, Lilly, Merck Sharp & Dohme, Novartis-Sandoz, Pfizer, R-Pharm, Roche, Samsung, Sanofi and UCB., (© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results